Lenalidomide
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00480 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 21 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | myeloid leukemia | KG + DL |
| 2 | unclassified myelodysplastic syndrome | KG + DL |
| 3 | refractory cytopenia of childhood | KG + DL |
| 4 | aregenerative anemia | KG + DL |
| 5 | severe congenital hypochromic anemia with ringed sideroblasts | KG + DL |
| 6 | partial deletion of the long arm of chromosome 5 | KG + DL |
| 7 | lymph node cancer | KG + DL |
| 8 | blast phase chronic myelogenous leukemia, BCR-ABL1 positive | KG + DL |
| 9 | ganglioneuroblastoma (disease) | KG + DL |
| 10 | acute lymphoblastic leukemia (disease) | KG + DL |
| 11 | vertebral anomalies and variable endocrine and T-cell dysfunction | KG + DL |
| 12 | neuroblastoma | KG + DL |
| 13 | retroperitoneal neoplasm | KG + DL |
| 14 | indolent plasma cell myeloma | KG + DL |
| 15 | Ewing sarcoma | KG + DL |
| 16 | acute lymphoblastic/lymphocytic leukemia | KG + DL |
| 17 | chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation | KG + DL |
| 18 | pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma | KG + DL |
| 19 | chronic myelogenous leukemia, BCR-ABL1 positive | KG + DL |
| 20 | refractory hematologic cancer | KG + DL |
| 21 | acquired secondary polycythemia | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.